NCT00394628Unknown1 期
A Phase 1b/2a, Multicenter, Open-Label Study of AQ4N in Combination With Radiation Therapy and Temozolomide, to Evaluate the Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme
适应症
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- Novacea
- 入组人数
- 60
- 试验地点
- 5
- 主要终点
- Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODAR®)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.
研究概览
简要总结
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels.
Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven intracranial Glioblastoma Multiforme (GBM) with diagnosis established by biopsy or resection within 5 weeks prior to enrollment.
- •Cranial MRI or contrast CT performed 14 days prior to study entry. Subjects without measurable or assessable disease are eligible.
- •Plan to begin partial brain radiotherapy within 24-72 hours after beginning AQ4N, and within 35 days (5 weeks) of the surgery, or if surgery cannot be performed, the biopsy that confirms GBM diagnosis. Radiation therapy must be given by external beam to a partial brian field in daily fractions of 2.0 Gy, to a planned total dose to the tumor of 60.0 Gy over 6 weeks.
- •Age equal to or greater than 18 years and life expectancy > 10 weeks.
- •Karnofsky performance status of >
- •Adequate bone marrow, liver and renal functions (tests must be performed within 14 days prior to enrollment).
- •Negative serum or urine pregnancy test (females of childbearing potential only).
- •Willingness to use effective contraception (both males and females of child-bearing potential) throughout the study and for at least 2 months after study treatment.
- •Able and willing to give informed consent.
排除标准
- •Previous radiotherapy to the brain.
- •Previous cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor. Subjects who received Gliadel wafers will be excluded.
- •Subjects previously treated with enzyme-induced antiepileptic drugs (EIAEDs) must have discontinued treatment with these agent(s) greater than or equal to 2 weeks prior to enrollment.
- •A history of any other primary malignancy that has not been treated with curative intent and that has not been in complete remission for at least 2 years (exempt from the two year limit are non-melanoma skin cancer and cervical carcinoma in-situ on biopsy or a squamous intraepithelial lesion on PAP smear).
- •Active infection.
- •Any significant medical illnesses or toxicities that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the subjects' ability to tolerate this therapy. Subjects must not have any disease that will obscure toxicity or dangerously alter drug metabolism, e.g. congestive heart failure, moderate to severe liver and renal disease, other cancers.
- •Cardiac ejection fraction (LVEF) by multiple gated acquisition scan (MUGA) less than the institutional lower limit of normal.
- •Prior investigational therapy within the past 28 days.
- •Prior AQ4N therapy.
- •Hypersensitivity to AQ4N or to any ingredients contained in the drug formulation.
- •Hypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine (DTIC).
- •Pregnant or lactating women.
结局指标
主要结局
Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODAR®)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.
Phase 2a: Rate of progression-free survival at 6 months.
次要结局
- Phase 2a: Rate of progression-free survival at 12 months
- Percent of subjects alive at 12 months
- Duration of progression-free survival
- Time to progression
- Duration of overall survival
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06700499Akeso450
已完成
1 期
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerBreast CancerNCT03800836Hoffmann-La Roche139
招募中
1 期
Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis BChronic Hep BChronic Hepatitis bHBVChronic HepatitisNCT06671093Tune Therapeutics, Inc.36
已完成
1 期
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerHead and Neck CancerHuman Papilloma VirusNCT03162224MedImmune LLC35
已完成
1 期
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult VolunteersCOVID-19 VaccineNCT05188469EyeGene Inc.67